These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37663575)

  • 1. The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review.
    Debrabander Q; Hensley KS; Psomas CK; Bramer W; Mahmoudi T; van Welzen BJ; Verbon A; Rokx C
    J Virus Erad; 2023 Sep; 9(3):100342. PubMed ID: 37663575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells.
    Baker EJ; Hughes K; Travieso T; Klotman ME; Blasi M
    J Virol; 2022 Jul; 96(14):e0062422. PubMed ID: 35867560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
    Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
    Darcis G; Bouchat S; Kula A; Van Driessche B; Delacourt N; Vanhulle C; Avettand-Fenoel V; De Wit S; Rohr O; Rouzioux C; Van Lint C
    AIDS; 2017 Jan; 31(2):181-189. PubMed ID: 27755105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
    Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
    Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
    Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
    Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
    J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
    Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
    Front Immunol; 2018; 9():3162. PubMed ID: 30723480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HIV-1 latency reversal and antibody-dependent viral clearance by quantification of singly spliced HIV-1
    Gao H; Ozantürk AN; Wang Q; Harlan GH; Schmitz AJ; Presti RM; Deng K; Shan L
    J Virol; 2021 May; 95(11):. PubMed ID: 33762408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.